Breast Cancer series

The breast cancer series aims to highlight these key issues and foster focused discussions amongst UICC members and renowned experts on key actions needed to reduce the global breast cancer burden.

Virtual Dialogues series: Breast Cancer

A series of Virtual Dialogues bringing the breast cancer community together to tackle the growing breast cancer burden

Despite advances and progress seen in breast cancer in recent years, current data highlights that breast cancer incidence and mortality remain the highest for cancer in women, with nearly 2.3 million new cases and an estimated 665,675 deaths in 2022This trend is expected to accelerate in the next 20 years, with a disproportionate number of cases and deaths expected to occur in low-resource settings.

To tackle the growing breast cancer burden, it is critical that improvements are made in

  • early detection;
  • timely access to treatment and care;
  • availability of palliative and survivorship care;
  • comprehensive data collection through robust cancer registries.

The breast cancer series aims to highlight these key issues and foster focused discussions amongst UICC members and renowned experts on key actions needed to reduce the global breast cancer burden.

Series dialogues

Breast Cancer series: Closing the care gap in metastatic breast cancer

Virtual Dialogues series - Breast cancer
Read more

Special Focus Dialogue: Rethinking Pink October – how to increase engagement with the public virtually

Breast Cancer Awareness Month Pink ribbon
Read more

Special Edition Dialogue - World Cancer Day for breast cancer groups

Read more

Special Focus Dialogue - Early breast cancer detection

Read more

Special Focus Dialogue - A walk through the Knowledge Summaries on Breast Cancer control

Read more

This series is part of the UICC's Breast Cancer programme.

It is supported by Pfizer (Founding Partner), Daiichi Sankyo, Revolution Watch, the US National Cancer Institute Center for Global Health, Roche, Novartis and Susan G. Komen, in collaboration with the Breast Health Global Initiative, and WHO's Global Breast Cancer Initiative

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines, and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.

Revolution Media was founded in 2004 with the aim of bringing the very best watch-related content to readers everywhere.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures. Visit or call 1-877 GO KOMEN. Connect with us on social at

In collaboration with:

BHGI develops, implements and studies evidence-based, economically feasible, and culturally appropriate Guidelines for International Breast Health and Cancer Control for low- and middle-income countries (LMICs), to improve breast health outcomes and access to breast cancer screening, detection and treatment for women.

Founded in 1948, WHO is the United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health. WHO leads global efforts to expand universal health coverage. They direct and coordinate the world’s response to health emergencies. And they promote healthier lives – from pregnancy care through old age.

Read more

UICC's Virtual Dialogues provide members, and the cancer community, with regular opportunities to connect, exchange knowledge, access expert insights, and share solutions from the comfort of one's office or home.

A variety of glasses containing different alcohol

UICC and the Canadian Partnership Against Cancer are organising a series of discussions looking at alcohol and cancer to help better inform and connect the cancer community.

Tobacco control Virtual Dialogue

UICC aims to engage all key stakeholders in the tobacco control and cancer communities in discussing key actions to ensure global committments on tobacco control translate into national policy actions ultimately leading to a reduction in the burden of tobacco-related cancer and other diseases.

Virtual Dialogues series: Cervical cancer elimination

In this series UICC and partners bring global health leaders, advocates and policymakers together to discuss the challenges and solutions to creating an enabling environment towards the 90:70:90 targets by 2030.

Cancer and COVID19 series

UICC invited the cancer community to reflect on some of the changes set in motion by COVID-19, and discuss the implications for cancer prevention and control.

Last update

Monday 12 February 2024

Share this page